Your browser doesn't support javascript.
loading
Meta-analysis: combination of meropenem vs ceftazidime and amikacin for empirical treatment of cancer patients with febrile neutropenia.
Wang, Ying; Du, Zhichao; Chen, Yongdong; Liu, Yugang; Yang, Zhitang.
Affiliation
  • Wang Y; Department of Pharmacology, Medical College and Affiliated Hospital of Hebei University of Engineering.
  • Du Z; Department of Pharmacology, Medical College and Affiliated Hospital of Hebei University of Engineering.
  • Chen Y; Department of Orthopedics.
  • Liu Y; Department of Orthopedics.
  • Yang Z; Department of Neurology, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, PR China.
Medicine (Baltimore) ; 100(8): e24883, 2021 Feb 26.
Article in En | MEDLINE | ID: mdl-33663117
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Amikacin / Ceftazidime / Febrile Neutropenia / Meropenem / Anti-Bacterial Agents Type of study: Clinical_trials / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Medicine (Baltimore) Year: 2021 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Amikacin / Ceftazidime / Febrile Neutropenia / Meropenem / Anti-Bacterial Agents Type of study: Clinical_trials / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Medicine (Baltimore) Year: 2021 Document type: Article